Robert Popp

Genome British Columbia

Papers

1

Total Citations

40

H-Index

1

About

Robert Popp is a leading figure in clinical proteomics and mass spectrometry-based diagnostics, with a primary focus on the development of novel immunoaffinity-MALDI (iMALDI) assays for precise biomarker quantification. His most significant contribution is the creation and validation of an iMALDI assay for angiotensin I, a critical tool for measuring plasma renin activity (PRA) in the diagnosis of secondary hypertension. This work, published in 2013 and garnering over 40 citations, directly addresses the limitations of traditional radioimmunoassays—such as non-specificity, lengthy analysis times, and narrow calibration ranges—by offering a more specific, rapid, and robust alternative. Popp’s innovations have streamlined the screening process for secondary forms of hypertension, enhancing diagnostic accuracy in clinical settings. His research bridges analytical chemistry and clinical medicine, demonstrating how advanced mass spectrometry techniques can replace outdated methods. By pioneering iMALDI workflows, Popp has established a foundation for broader applications in peptide hormone analysis, cementing his impact on both translational proteomics and patient care.

Research Focus

Key Achievements

1
H-Index
1
Papers
40
Total Citations
40
Avg Citations/Paper
🏆 Most Cited Paper
Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension
40 citations · 2013
📈 Most Prolific Year: 2013 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: Genome British Columbia

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago